Insilico Medicine identified 28 new targets for the treatment of amyotrophic lateral sclerosis (ALS) using its proprietary AI-driven platform PandaOmics. Previously unreported 8 genes were shown to have functional connection with ALS and 64% of identified targets were successfully validated in a preclinical animal model. This gives a hope to solve an unmet need for ALS treatment.
This content available exclusively for BPT Mebmers
Topics: Novel Therapeutics